VABILO NA SEMINAR NIB: "Clinical and Translational Immunotherapy Studies in Pediatric Acute Myeloid Leukemia", dr. Richard Aplenc


Nacionalni inštitut za biologijo Vas vabi, da se udeležite seminarja

"Clinical and Translational Immunotherapy Studies in Pediatric Acute Myeloid Leukemia",

ki ga bo predstavil

dr. Richard Aplenc, MD, PhD

Mai and Harry F. West Endowed Chair in Pediatric Research

Professor of Pediatrics and Epidemiology

AVP and Chief Clinical Research Officer

The Children's Hospital of Philadelphia

Perelman School of Medicine at the University of Pennsylvania

Seminar bo v ponedeljek, 6. marca 2023, ob 13. uri

v Biološkem središču, Večna pot 111, v Ljubljani, v predavalnici B3.


Pediatric acute myeloid leukemia (AML) is the second most common pediatric leukemia and currently employs the most intensive chemotherapy regimens used in pediatric oncology. Despite this treatment intensity, approximately one half of patients treated in the United States will experience AML relapse and only one third of those patients can be cured with standard salvage therapies. Thus, new therapies for pediatric AML are very much needed. In this presentation, I will provide background on the treatment and outcomes of pediatric AML in the United States, describe our ongoing work to identify novel immunotherapy targets for chimeric antigen receptor (CAR) therapy, and review data from the CD123 CAR trial currently open at the Children's Hospital of Philadelphia.

Vljudno vabljeni. Predavanje bo potekalo v angleškem jeziku.

Dodatne informacije: dr. Anže Smole, anze.smole@nib.si, Katja Sinur katja.sinur@nib.si .